Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
_Cancer Research Journal - This journal ceased publication after 4#4 (2010). Back Issues are available.
$195.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Tardive Dyskinesia: Current Approach
Tell A Friend
 
Tell someone you know about this product.
Tardive Dyskinesia: Current Approach
Retail Price: $95.00
10% Online Discount
You Pay:

$85.50
Editors: Chanoch Miodownik, M.D. and Vladimir Lerner, M.D., Ph.D. (Ben-Gurion University of the Negev, Division of Psychiatry, Head of Closed Department, Be’er Sheva Mental Health Center, Be’er-Sheva, Israel)
Book Description:
Abnormal involuntary dyskinetic movements in schizophrenia patients have been documented for more than 140 years. However, after introducing into clinical practice antipsychotic medications, movement disturbances became a relatively frequent phenomenon. Medication-induced movement disorders are divided into two groups: a) acute, which appears during several hours or days after beginning treatment with psychotropic medications, and b) delayed or tardive motor disturbances that occur after months or years of taking psychotropic drugs. In the term’s present meaning, the latter are iatrogenic, neurological, hyperkinetic movement disturbances characterized by repetitive, involuntary, purposeless movements in the oral/lingual/buccal area, body or choreoathetoid movements of the extremities.
Tardive movement disorder (TMD) is a serious, disabling and potentially permanent pathology. The pathogenesis of TMD remains unclear, and the pathophysiology is complex, multifactorial, and still not fully understood. Moreover, there is solid evidence of a genetic predisposition to these disturbances.
Abnormal movements should appear during exposure, or within four weeks of withdrawal from oral psychotropic medications or eight weeks from depot formulations. The minimal exposure to these drugs should be three months, except for patients older than 60, who can develop TMD after its use for one month. Finally, the movements should be present for at least one month to fulfill the criteria for TMD.
Several distinct forms of TMD exist, specifically tardive akathisia, tardive blepharospasm, tardive dystonia, tardive gait, tardive myoclonus, tardive tremor, and tardive tics, and they have different pathophysiologies and treatment.
The advent and widespread use of a new generation of antipsychotics in clinical practice had been expected to dramatically reduce the incidence and prevalence of TMD, however the reduction, if any, was modest. A number of drugs were tried for the management of this motor disturbance, yet until now no effective and standard treatment has been found. Therefore, the management of this motor disturbance remains an actual topic as well as a challenge for clinicians.
Although much has been written about TMD, this is obviously not a new clinical issue. Awareness of these motor disturbances as a result of medication treatment is a vital step toward intervention in the pathological process. Furthermore, it will be helpful for the protection and prevention of serious complications, while also allowing for greater access to clinicians in overall areas of medicine.
The authors believe that a better understanding of TMD will strengthen the efforts and success of effective diagnosing, prevention and treatment of this condition. (Nova Medicine and Health)


We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.


Table of Contents:
Introduction

Chapter 1. The History of Tardive Dyskinesia (pp. 1-12)
(Paul P. Lerner and Chanoch Miodownik)

Chapter 2. Etiology, Pathophysiology, and Imaging of Tardive Dyskinesia (pp. 13-40)
(Chanoch Miodownik and Vladimir Lerner)

Chapter 3. Risk Factors and Epidemiology of Tardive Dyskinesia (pp.41-62)
(Elyse Cornett, Katie Vancheire, Stephanie Ferrell and Daniel Core)

Chapter 4. Phenomenology of Tardive Syndromes: Clinical Presentation and Manifestations (pp. 63-78)
(Musa Usman Umar)

Chapter 5. Differential Diagnosis of Tardive Movement Disorders and Assessment Scales (pp. 79-118)
(Hani Raoul Khouzam and Anca Luminare)

Chapter 6. Treatment of Tardive Dyskinesia (pp. 119-148)
(Uma Suryadevara, Richard Holbert and Daniel Witter)

Chapter 7. Antioxidants as a Treatment of Tardive Movement Disorders (pp. 149-188)
(Chanoch Miodownik and Vladimir Lerner)

About the Editors (pp. 189-190)

Index (pp. 191)

Total Pages: 195

   Series:
      Rare Disorders Research Progress
   Binding: Softcover
   Pub. Date: 2018-August
   ISBN: 978-1-53613-776-7
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Tardive Dyskinesia: Current Approach